HCWB
HCW Biologics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
RSI Oversold
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HCWB
Hcw Biologics Inc.
A clinical-stage biopharmaceutical company that develops immunotherapes for the treatment of age-related diseases
2929 N Commerce Parkway, Miramar, Florida 33025
--
HCW Biologics Inc., was incorporated in Delaware on April 2, 2018. The company is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to extend the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company believes that age-related chronic low-grade inflammation, or "inflammation," is an important factor in several diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative disease and autoimmune disease.
Company Financials
EPS
HCWB has released its 2025 Q2 earnings. EPS was reported at -6.79, versus the expected -2.3, missing expectations. The chart below visualizes how HCWB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HCWB has released its 2025 Q2 earnings report, with revenue of 6.55K, reflecting a YoY change of -98.94%, and net profit of -1.93M, showing a YoY change of 87.38%. The Sankey diagram below clearly presents HCWB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
